Smith & Nephew swoops for US medicine firm in £500m deal
Smith & Nephew, the Hull-headquartered medical technology firm, has agreed to acquire a US-based regenerative medicine business in a deal worth more than £500m.
Osiris Therapeutics delivers regenerative medicine products, including skin, bone graft and articular cartilage substitutes.
The Nasdaq-listed firm delivered revenues of $102m for the nine months ending 30 September 2018, an 18.7% increase over the same period in 2017.
Smith & Nephew have valued Osiris’ shares at $19 each, representing a total equity value... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...